Analyst Price Target is $85.00
▼ -11.76% Downside Potential
This price target is based on 6 analysts offering 12 month price targets for Novartis in the last 3 months. The average price target is $85.00, with a high forecast of $85.00 and a low forecast of $85.00. The average price target represents a -11.76% upside from the last price of $96.33.
Current Consensus is
The current consensus among 6 polled investment analysts is to hold stock in Novartis. This Hold consensus rating has held steady for over two years.
Novartis AG researches, develops, manufactures, and markets healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.